Cargando…
Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES
BACKGROUND: Osteoporosis (OP) and osteopenia are common bone disorders in old age, and lots of patients suffering from OP or osteopenia need to take antiplatelet agents to treat basic diseases. However, clinical data on the link between osteopenia or OP and antiplatelet agents are limited. METHODS:...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396674/ https://www.ncbi.nlm.nih.gov/pubmed/36017309 http://dx.doi.org/10.3389/fendo.2022.945159 |
_version_ | 1784771979231887360 |
---|---|
author | Lv, Hao Wang, Jiuxiang Zhu, Yujun Hu, Zhimu Wang, Ziwen Qiao, Mingzhu Jiang, Ting |
author_facet | Lv, Hao Wang, Jiuxiang Zhu, Yujun Hu, Zhimu Wang, Ziwen Qiao, Mingzhu Jiang, Ting |
author_sort | Lv, Hao |
collection | PubMed |
description | BACKGROUND: Osteoporosis (OP) and osteopenia are common bone disorders in old age, and lots of patients suffering from OP or osteopenia need to take antiplatelet agents to treat basic diseases. However, clinical data on the link between osteopenia or OP and antiplatelet agents are limited. METHODS: Data in this study were collected and screened from the NHANES from 2013 to 2014 and 2017 to 2018. The variables were extracted from interviews and compared between OP or osteopenia participants and normal. The relationship between OP or osteopenia and taking antiplatelet drugs was analyzed by weighted multivariate logistic regression RESULTS: After excluding individuals who were not eligible and had invalid data, we finally identified 894 participants for inclusion in the study. We found a negative association between OP or osteopenia and taking antiplatelet agents (OR = 0.53; 95% CI, 0.33–0.84; p < 0.05). These results did not change on multiple imputations (OR = 0.32, 95% CI, 0.19–0.56; p <0.01). In the subgroup analyses, the associations were more significant in women (OR = 0.18, 95% CI, 0.05–0.62; p <0.05). CONCLUSION: This study demonstrated that the association between OP or osteopenia and taking antiplatelet agents was significant. Therefore, it is necessary to confirm the result by extending further research. |
format | Online Article Text |
id | pubmed-9396674 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93966742022-08-24 Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES Lv, Hao Wang, Jiuxiang Zhu, Yujun Hu, Zhimu Wang, Ziwen Qiao, Mingzhu Jiang, Ting Front Endocrinol (Lausanne) Endocrinology BACKGROUND: Osteoporosis (OP) and osteopenia are common bone disorders in old age, and lots of patients suffering from OP or osteopenia need to take antiplatelet agents to treat basic diseases. However, clinical data on the link between osteopenia or OP and antiplatelet agents are limited. METHODS: Data in this study were collected and screened from the NHANES from 2013 to 2014 and 2017 to 2018. The variables were extracted from interviews and compared between OP or osteopenia participants and normal. The relationship between OP or osteopenia and taking antiplatelet drugs was analyzed by weighted multivariate logistic regression RESULTS: After excluding individuals who were not eligible and had invalid data, we finally identified 894 participants for inclusion in the study. We found a negative association between OP or osteopenia and taking antiplatelet agents (OR = 0.53; 95% CI, 0.33–0.84; p < 0.05). These results did not change on multiple imputations (OR = 0.32, 95% CI, 0.19–0.56; p <0.01). In the subgroup analyses, the associations were more significant in women (OR = 0.18, 95% CI, 0.05–0.62; p <0.05). CONCLUSION: This study demonstrated that the association between OP or osteopenia and taking antiplatelet agents was significant. Therefore, it is necessary to confirm the result by extending further research. Frontiers Media S.A. 2022-08-09 /pmc/articles/PMC9396674/ /pubmed/36017309 http://dx.doi.org/10.3389/fendo.2022.945159 Text en Copyright © 2022 Lv, Wang, Zhu, Hu, Wang, Qiao and Jiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Lv, Hao Wang, Jiuxiang Zhu, Yujun Hu, Zhimu Wang, Ziwen Qiao, Mingzhu Jiang, Ting Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES |
title | Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES |
title_full | Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES |
title_fullStr | Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES |
title_full_unstemmed | Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES |
title_short | Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES |
title_sort | association between osteoporosis or osteopenia and taking antiplatelet agents in general us population of nhanes |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396674/ https://www.ncbi.nlm.nih.gov/pubmed/36017309 http://dx.doi.org/10.3389/fendo.2022.945159 |
work_keys_str_mv | AT lvhao associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes AT wangjiuxiang associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes AT zhuyujun associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes AT huzhimu associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes AT wangziwen associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes AT qiaomingzhu associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes AT jiangting associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes |